AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research
An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II…
An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
A deal between Swiss biotech AC Immune and Eli Lilly to develop an oral Alzheimer’s…
AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins…
The biotech industry has often been criticized for its lack of gender diversity. While there…
The Swiss city of Lausanne is perhaps best known as a hub of international sport,…
Today, March 8, is international women's day. To celebrate the achievements of women we're revisiting…
As the 2017 reports roll in, we're already turning our gaze to 2018. These are…
Efforts to treat Alzheimer’s Disease have been hit with failure after failure in the last…
AC Immune's Anti-Tau antibody for the treatment of Alzheimer's disease has reached Phase II, prompting…
Probiodrug has disclosed encouraging results of its latest Phase IIa trial to assess its lead…
The Swiss biotech AC Immune announced that its partner Genentech (Roche) will start a second phase…